If consumption of Global Health Impact goods reaches one percent of the market in generic and over-the-counter medications alone, that will create about $360 million-worth of incentives for pharmaceutical companies become Global Health Impact certified by expanding access to effective medicines needed by the global poor. Global Health Impact certification will open the door to other ways of incentivizing positive change. Universities can, for instance, license more of their products to highly rated companies. Just to one percent of the university research and technology market is worth some $840 million, enough to double the number of drugs produced for neglected diseases.
Most of the world’s health problems afflict the global poor. So we reward companies that focus on meeting this need.
Many poor people cannot access the existing drugs and technologies they need. So we reward companies that lower prices and do other things to increase access.
Little of the research and development on new drugs and technologies benefits the poor. So we reward companies that create new effective interventions that benefit he poor.